|
Company Name: Agenix Limited
Company Type: Medical and Veterinary Diagnostics
Company Profile
• This company produces medical and veterinary diagnostic products based on monoclonal antibody technology. Special fields include human haemostasis and infectious diseases.
Agenix Limited was listed on the Australian Stock Exchange in October 1987. It currently has revenues of $16 million, largely derived from sales of products developed by its wholly-owned operating subsidiary AGEN Biomedical Limited. Agenix has a well-established strong presence in the market for cardiovascular diagnostic products and its 3B6 antibody is recognised as the most specific available for the detection of blood clots. The company has modern manufacturing facilities in Brisbane approved under the US Food and Drug Administration, US Department of Agriculture and Australian Therapeutic Goods Administration.
Agenix employs a strategic blend of biotechnology investment in research and development of ThromboView®, an innovative blood-clot imaging technology targeting a global US$3 billion market, and a strong commercial foundation as manufacturer of Human Health diagnostic products that are leaders in their market segments. ThromboView® has recently completed a successful Phase I/II clinical trial program in Australia, the US and Canada. The product showed strong signals of efficacy in its ability to localise clots in the thigh and in the lungs. Planning is now underway to initiate a Phase II study in the diagnosis of Pulmonary Embolism in the US and Canada in Q2 2007.
In March 2003 the ASX issued the results of a review of corporate governance by the ASX Corporate Governance Council. These results included ten PRINCIPLEs of good corporate governance and twenty eight Best Practice recommendations. The Board of Directors of Agenix Limited has reviewed these recommendations and the following summary outlines the Company's approach in relation to those recommendations. Unless otherwise stated, Agenix's corporate governance practices are in place and comply with the Council's Best Practice recommendations. The Board is responsible for the corporate governance of the economic entity. The Board guides and monitors the business affairs of Agenix Limited on behalf of the shareholders by whom they are accountable.
About Company
Our Vision
Agenix aims to continue to be at the forefront of biotechnology, with a major focus on the development of monoclonal antibodies into innovative medical products.
Corporate Overview
Agenix Limited is a leading edge biotechnology company with operations through its wholly owned subsidiary AGEN Biomedical Limited ("AGEN")
AGEN specialises in advanced medical diagnosis of human diseases and is well positioned as a world-class thrombosis and blood clot specialist. Building on existing technology platforms, AGEN is continuously investing in research and development. AGEN is in the process of commercialising a breakthrough technology in blood clot imaging called ThromboView®.
|
